Medtronic (MDT) announced U.S. FDA 510(k) clearance of its MiniMed Go app. The MiniMed Go Smart Multiple Daily Injection system seamlessly integrates the InPen smart insulin pen with the Instinct sensor made by Abbott – all connected through the MiniMed Go app. The MiniMed Go system is cleared for individuals with insulin-requiring type 1 and type 2 diabetes aged 7 years and older, as well as for children ages 2 to 6 years under the supervision of an adult caregiver. Compatibility of the Simplera sensor with MiniMed Go is currently under FDA review.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $112 from $111 at Bernstein
- Medtronic price target raised to $116 from $111 at Barclays
- 3 Best Dividend Aristocrat Stocks to Buy Now, 01/07/2026
- CoreWeave initiated, Shopify downgraded: Wall Street’s top analyst calls
- Medtronic upgraded to Outperform from Market Perform at William Blair